Semaglutide Use in Patients with Pancreatitis History

Guideline-Based Recommendations

The American College of Cardiology recommends using liraglutide with caution in patients with a history of pancreatitis, and this guidance extends to semaglutide 1
Discontinue semaglutide immediately if pancreatitis is suspected and do not restart if pancreatitis is confirmed, as advised by the American College of Cardiology 2
Monitor for signs and symptoms of pancreatitis, including persistent severe abdominal pain, when prescribing semaglutide to patients with a history of pancreatitis, according to the American College of Cardiology 4

The LEADER trial with liraglutide did not demonstrate increased pancreatitis risk, although the FDA and European Medicines Agency have not established a definitive causal link between GLP-1RAs and acute pancreatitis, as reported by the American College of Cardiology 4

For patients with a history of pancreatitis, the American College of Cardiology recommends selecting an alternative glucose-lowering medication, such as SGLT2 inhibitors, DPP-4 inhibitors, or metformin, as a first-line approach 4, 1
If semaglutide is being considered despite history, document clear rationale for why alternative therapies are inadequate, obtain baseline lipase and amylase levels, evaluate for other pancreatitis risk factors, start at the lowest dose, and provide explicit patient education about pancreatitis symptoms, as suggested by the American College of Cardiology and Praxis Medical Insights 5, 4

Patients with severe renal impairment require cautious use and monitoring of semaglutide, according to the American College of Cardiology 1
Patients with diabetic retinopathy require ophthalmologic evaluation within 12 months of semaglutide initiation, as recommended by the American College of Cardiology 4
Concomitant insulin or sulfonylurea use requires dose reduction to prevent hypoglycemia when using semaglutide, according to the American College of Cardiology 1